I
nflammatory bowel diseases (IBD)-Crohn's disease (CD) and ulcerative colitis (UC)-are chronic conditions that commonly affect young patients. In fact, the highest age-and sex-adjusted incidence rates occur during the peak reproductive years, and reproductive issues are of key concern to these patients. 1, 2 In addition, as medical therapy of IBD evolves, more patients are healthy enough to consider conception. 3 Male fertility is evaluated by analysis of the quality of semen (semen study). The results obtained are compared either against standard parameters defined by the recommendations of World Health Organization (WHO) 4, 5 or, ideally, against a control group from the same geographical area.
Data on fertility rates and medication safety in IBD are limited, especially in men, and several factors have been associated with impaired male fertility. 6 Specifically, it has been suggested that paternal smoking habits can adversely affect the success rate of assisted reproduction procedures. A link between smoking and altered semen parameters has been recognized. However, the relationship between smoking and male fertility is still under debate. 7, 8 The effects of some therapies used to treat IBD on fertility have been studied. Numerous studies have described that sulfasalazine causes reversible oligospermia, which resolves with discontinuation of therapy. However, methotrexate is associated with oligospermia and is a potent teratogen. The available data on the risk of fetal teratogenicity with paternal azathioprine and mercaptopurine use are limited, and studies have yielded variable results. Treatment with azathioprine does not reduce semen quality as measured by sperm density, motility, morphology, ejaculate volume, or total sperm count. [9] [10] [11] [12] [13] [14] Cytokines, especially tumor necrosis factor alpha (TNF-a), are present in human sperm, but their effects on semen quality are also a matter of debate. 15 Infliximab and adalimumab are biological agents of the anti-TNF-a class that have shown efficacy in the induction and maintenance of remission for patients with IBD. Studies performed in men with CD treated with infliximab have shown a reduction in sperm motility and altered morphology. 16 Whether these results lead to impaired fertility has not been formally analyzed. However, studies performed in patients with spondyloarthritis concluded that these medications do not damage testicular function or spermatogenesis. 17, 18 The effect of adalimumab on male fertility has not been studied.
Humoral immunity against sperm antigens based on crossreactivity between spermatozoa and exogenous antigens has been considered as a potential reason for human infertility. Circulating antibodies to human spermatozoa have been detected in patients with UC, 19, 20 but their relationship with infertility in IBD remains unclear.
In addition, zinc plays an essential role in male fertility. Although zinc deficiency-which may indicate reduced zinc absorption or increased zinc losses-is a well-known feature of CD, the relation between zinc deficiency and male subfertility in CD remains unclear. [21] [22] [23] The aim of the present study was to evaluate whether there is a seminal alteration in patients diagnosed with IBD in comparison with the control group and, if so, to evaluate the mechanisms that may play a role according to what has been previously described in the literature, including an alteration in the metabolism of zinc, sexual hormones, IBD activity, major autoimmunity (anti-sperm antibodies), and IBD therapy. Its secondary aim was to evaluate the impact of IBD on male sexual function in men.
MATERIALS AND METHODS

Patients and Control Subjects
A cross-sectional case series study comparing men with IBD and healthy controls was undertaken. Male patients attending outpatient IBD clinics of the 4 participating university hospitals were consecutively asked to enroll in the study. Patients were recruited over 3 years (March 2012 to March 2015) and only patients who fulfilled the inclusion and exclusion criteria (defined below) were enrolled in the study.
The subjects who participated as controls were healthy volunteers (medicine students and partners of the patients with IBD), who had neither been previously studied nor had they previously gone to a medical consultation because of fertility problems. All participants signed an informed consent form before enrolment.
The inclusion criterion for cases and control subjects was age (between 18 and 45 years). The exclusion criteria were presence of varicocele, altered follicle-stimulating hormone, luteinizing hormone, prolactin (PRL) or testosterone levels, or any pathology related to subfertility (e.g., cryptorchidism). Other exclusion criteria were presence of $5 white blood cells in semen analysis, .3 white blood cells per high-power field, or a positive semen culture.
The history of diabetes, hypertension, drugs, and toxins, which may affect the quality of the semen, and the quality of the sexual life of men were evaluated in the basal medical history.
All the subjects had to go through an anamnesis specially aimed at fertility problems, and a physical examination was carried out and an analysis of hormonal levels was undertaken. Any patient in whom an anomaly was identified was transferred for further study to the Urology Department and was excluded from this study.
The variables of interest to this study were age, smoking habit, IBD subtype (CD or UC), disease extent (Montreal classification), disease duration, and IBD treatment, where applicable.
To determine IBD activity, the Harvey-Bradshaw Index for CD and the Simple Clinical Index for UC [24] [25] [26] were used. Information on acute-phase reactant levels was obtained through laboratory tests.
The impact of IBD on male sexual function was evaluated using the International Index of Erectile Function (IIEF-15), validated in the participants' native language. [27] [28] [29] The IIEF-15 is an index designed to evaluate mainly the sexual dysfunctions in men and is accepted as the preferred assessment for clinical trials involving erectile dysfunction. It includes 15 variables classified in 5 categories (erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction). These categories are evaluated as: no dysfunction, mild dysfunction, mild to moderate or severe, according to the points obtained in each category. Points are awarded according to the level of function, with higher values indicating a better sexual function. The maximum global score is 75 points, with sexual function considered to be healthy for global scores above 43 points. The global score and 5 domainspecific scores related to sexual function (erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction) were assessed.
Laboratory Samples
All participants received clear written instructions on semen specimen collection according to the WHO's recommendations. 4, 5 Semen samples were collected after a minimum of 3 and a maximum of 5 days of sexual abstinence. Only complete samples obtained by masturbation and collected into a plastic container were evaluated after labelling them with the date and time of collection. Semen analysis evaluated sperm count (million/mL), motility (progressive motility or a + b motility), morphology, and vitality.
According to the WHO's recommendations, "a" motility is the rapid and progressive motility of sperm in the semen study, "b" motility is the slow and progressive mobility of sperm in the semen study; a + b motility is, then, the sum of the 2, which is the total sum of mobile sperm in a semen study. This sum must reach a minimum of 32% according to the WHO criteria. The WHO criteria for normozoospermia are a sperm concentration of $15 million/mL, "a + b" motility of $32%, and normal morphologies of .4%.
Anti-sperm antibodies in semen were detected by the SperMarIgA test (FertiPro N.V., Beernem, Belgium).
To evaluate nutritional status, levels of vitamin B 12 , folic acid, and albumin in peripheral blood samples were analyzed. All patients had fasted before blood collection.
Hormone concentrations (follicle-stimulating hormone, luteinizing hormone, PRL, and free testosterone), C-reactive protein (CRP), plasma and seminal fluid zinc levels, 24-hour urinary zinc levels and plasma TNF-a levels were also determined.
Statistical Analysis
Qualitative variables were summarized by frequency distribution, and quantitative variables as mean values and SDs. Continuous, non-normally distributed variables were expressed as medians and interquartile ranges.
For qualitative variables, comparisons between study groups (CD, UC, and control subjects) were performed by the chi-square test. Comparisons among all 3 groups were performed through 1-way analysis of variance for quantitative, normally distributed variables or through the nonparametric Kruskal-Wallis test for non-normally distributed variables.
Differences in the outcome variables (semen analysis and IIEF-15 scores) were evaluated through analysis of covariance, with adjustment for confounders (sociodemographic characteristics and hormone levels). Sperm count values were not normally distributed and were thus log-transformed. The same analysis strategy was used for comparisons between CD and UC, excluding patients on anti-TNF therapy. The relationship between quantitative variables was evaluated through Pearson correlation coefficients. The null hypothesis was rejected by a type I error less than 0.05 (P , 0.05).
Statistical analysis consisted of the following: first, a univariate analysis to detect those factors that might have had an influence on the semen analysis; and second, a multivariate analysis was carried out where those significant variables in the preliminary analysis were included along with those variables that were considered clinically relevant. As a result, in the multivariate analysis, 3 variables were included (age, smoking habits, and PRL) and, in each comparison, the whole sample was used in each group because they were independent groups.
ETHICAL CONSIDERATIONS
This study was approved by the Research Ethics Committee of the steering center and was conducted in accordance with the Declaration of Helsinki.
RESULTS
Baseline Characteristics of Patients with IBD and Healthy Control Subjects
Of the 97 individuals who met the inclusion criterion, 8 refused to participate. Of the 89 subjects enrolled in the study, 74 were enrolled for analysis, with the following distribution: 30 CD (40.4%), 22 UC (29.7%), and 22 control subjects (29.7%) (Fig. 1) .
The patients with IBD were recruited as follows: 38 from Hospital Universitario de Fuenlabrada, 9 from Hospital Universitario de la Princesa, 4 from Hospital Universitario Fundación de Alcorcon, and 1 from Hospital Universitario Severo Ochoa. All the control subjects were recruited from Hospital Universitario de Fuenlabrada.
No control had to be excluded because none of them showed in the basal analysis test an alteration in their levels of sexual hormones or the presence of varicocele. Overall, 92% of patients were in clinical remission at the time of enrolment, with a median Harvey Index of 1 (interquartile range: 0-1) and a Simple Clinical Index of 1 (0-1), respectively. Only 5 patients (4 CD and 1 UC) had mild activity, with a Harvey Index of 5 points and a Simple Clinical Index of 3 points, respectively. Comparisons across CD and UC revealed no differences in the activity of the disease. The disease duration at the time of inclusion was 9 6 5 years. The characteristics of patients with IBD are shown in Table 1 .
None of the subjects who participated in the study (all of them younger than 45 years) showed associated comorbidities (diabetes, hypertension) or a history of alcohol abuse, anabolic steroid, or street drugs consumption.
Evaluation of Semen Quality and Sexual Function in Patients with IBD and Control Subjects
The mean age was 30.5 6 5.5 years in the CD group, 34 6 6 years in the UC group, and 31.3 6 5.1 among control subjects (P ¼ 0.08). There were 14 smokers in the CD group, 8 in the UC group, and 8 in the control group (P ¼ 0.22).
Comparisons across the 3 groups (CD, UC, and control subjects) revealed no differences in follicle-stimulating hormone, luteinizing hormone, or testosterone levels. PRL levels were higher in the UC and CD groups compared with the control group, with P ¼ 0.06. Table 2 shows the univariant analysis used for evaluating confounding factors that might alter the semen analysis. Moreover, because age and smoking habits are considered clinically significant, 3 variables were included in the multivariant analysis (age, smoking habits, and PRL).
Patients with CD had lower sperm counts than control subjects or patients with UC (P ¼ 0.04). However, statistical significance disappeared when the results were adjusted for age, PRL level, and smoking status (P ¼ 0.16, Table 3 ). No differences in progressive motility, vitality, or morphology were found between the 3 groups (Table 3) .
Regarding immunosuppressive therapy, there were no differences between patients taking azathioprine and mercaptopurine and those who were not on these treatments, with a median sperm count of 35.5/mL (interquartile range: 19.7-69) versus 51 (24-100) (P ¼
Regarding male sexual function, no statistically significant differences were found across the 3 groups in global IIEF-15 score, erectile function, sexual satisfaction, orgasmic function, or sexual desire (Table 3) .
Patients with CD had lower seminal zinc levels than patients with UC and control subjects (P ¼ 0.02), with no difference in serum or urinary zinc (Table 4) .
Evaluation of Semen Quality and Sexual Function in Patients with CD and UC, Excluding Patients on Anti-TNF Therapy
Semen quality was analyzed to determine whether there were differences between patients with CD and UC. Twenty patients with CD and 21 patients with UC were included for this analysis. Patients on anti-TNF drugs were excluded due to the small sample size: only 1 patient, in the UC group, was receiving anti-TNF therapy.
Patients with CD had worse progressive motility and sperm concentration (oligoasthenozoospermia) (P ¼ 0.02), with no differences in vitality or morphology. However, the statistical significance for difference in motility was lost when results were adjusted for age, PRL, smoking status, and salicylate therapy (P ¼ 0.06, Table 5 ). To analyze the mechanisms that may play a role on oligoasthenozoospermia in CD, zinc levels, IBD activity, TNF-a, and presence of anti-sperm antibodies were evaluated. There were no differences in the activity of IBD between CD and UC.
All results for anti-sperm antibodies were negative. TNFa levels were similar in patients with CD and UC (median, 4.5 [1.7-7.3] pg/mL versus 4.4 [3.5-8.0] pg/mL, P ¼ 0.9).
Patients with CD had lower seminal zinc levels than patients with UC (mean 6 SD, 1475 6 235 mmol/L versus 2221 6 1123 mmol/L, P ¼ 0.04) with no differences in serum or urinary zinc.
Seminal zinc levels showed a positive correlation with progressive motility on sperm analysis (r ¼ 0.24, P ¼ 0.08. Fig.  2 ). There was no correlation between seminal and plasma zinc levels. No differences in IIEF-15 score were found between the CD and UC groups ( Table 5 ).
Influence of Anti-TNF-a Therapy on Semen Quality of Patients with CD
To evaluate the influence of anti-TNF drugs on fertility in CD, the results obtained in patients with CD treated with adalimumab and infliximab were compared with those results obtained in patients with CD not on this therapy. Thirty patients with CD (20 not on anti-TNF therapy, 6 treated with infliximab, and 4 with adalimumab) were included for analysis. All results were adjusted for age, PRL, and smoking status.
In addition, the influence of nutritional or inflammatory status (as measured by albumin, vitamin B 12 , folic acid, and CRP levels) was assessed in both groups. Patients with CD not on anti-TNF therapy had higher levels of albumin (mean 6 SD, 4.3 6 0.3 g/dL Patients on infliximab or adalimumab treatment also exhibited better progressive motility (P ¼ 0.01), morphology (P ¼ 0.04), and vitality (P ¼ 0.07) on sperm analysis compared with patients with CD who were not on anti-TNF therapy (Table 6 ).
No differences in urinary or seminal zinc levels were found, but patients with CD on anti-TNF therapy had lower serum zinc levels (P ¼ 0.03, Table 6 ). These results were not associated with the duration of treatment; only 5% of patients had been treated with biological agents, for less than 7 months.
Anti-TNF therapy was not associated with differences in IIEF-15 scores (P ¼ 0.60).
DISCUSSION
Patients with IBD and their families naturally wish to know whether disease activity and drug exposure could affect fertility, pregnancy outcomes, and the developing child. Few studies have evaluated impairment of fertility in men with IBD. For CD, 3 studies-2 population-based and 1 conducted at a single referral center-have evaluated fertility status. [30] [31] [32] The results showed that men with CD fathered fewer children even before being diagnosed with the illness, although in some cases, this was the patients' choice. As a result, CD shows a negative impact on fertility, but it cannot be concluded that the illness has a negative impact on semen quality.
There is no set value to determine when semen alterations involve a significant decrease in the ability to conceive. 33 As a result, in the study of the couple who consult because of a fertility alteration, the semen study is analyzed and the results compared against a control group or against the WHO established information of the normozoospermia. 4, 5 In our study, male patients with CD tended to have poorer semen quality, characterized by lower sperm count, reduced progressive motility, and lower seminal zinc levels than patients with UC. Because this is a cross-sectional study that has not evaluated the ability of the patients and their partners to conceive, we cannot draw sound conclusions regarding the patients' ability to conceive. Zinc is well known to play an essential role in male fertility. Although zinc deficiency (which may indicate reduced zinc absorption or increased zinc losses) has been described in CD, a possible association with male subfertility remains unclear. 22 Experimental studies with low-zinc diets in humans have shown that circulating zinc levels and activities of zinc-containing enzymes can be maintained within normal range over several months. [34] [35] [36] [37] Static indexes for assessment of zinc status, such as zinc concentration in plasma and urinary zinc excretion, are lower in severe zinc deficiency.
A positive link between seminal zinc concentration and sperm count has been established. Serum testosterone concentration, seminal volume, and total seminal loss per ejaculate are all sensitive to short-term zinc depletion in young men. 23 The effect of zinc levels on semen and its clinical importance has been described by several authors who have proved that the level of zinc in semen modified its motility and, hence, the quality of the semen. [21] [22] [23] In this study, men with CD, who showed a trend toward poorer semen quality, had urinary and plasma zinc levels similar to those of controls, so it is not possible to conclude that the CD population was zinc deficient. Nonetheless, static indexes are only altered when there is a severe deficit of zinc. Because in this study static indexes were used, these may have overestimated zinc status in the patients.
In addition, a positive correlation between seminal zinc levels and sperm motility was found. This supports the influence of zinc on fertility, as widely described.
Previous studies have suggested that medications used in the treatment of CD, including corticosteroids and azathioprine, do not influence fertility. 13, 14 This study's results in patients under thiopurine therapy confirm these previous results and enable clinicians to reassure male patients and their partners.
Regarding the physiology of fertility, cytokines-especially TNF-a-also have a role in reproduction. TNF-a is produced by germ cells in the testes under physiological conditions and is found at low levels in seminal plasma. Its presence in physiologically low levels within the male reproductive tract has effects on fertility. 15 In inflammatory conditions, higher TNF-a concentrations are detected in seminal fluid, and adverse effects on spermatogenesis have been reported, with reductions in sperm motility, viability, and motion parameters.
Previous studies have suggested that seminal motility and morphology are impaired in patients receiving infliximab for IBD. 16 Conflicting results were reported by Villiger et al 17 in patients with ankylosing spondylitis. Another prospective study 18 monitoring sperm parameters in patients with active spondyloarthritis before and after 12 months of anti-TNF therapy did not show a negative impact on sperm quality. Conversely, a trend toward improvement of sperm parameters and progressive motility was noted after 1 year of anti-TNF treatment. An in vitro study demonstrated that exposure of spermatozoa to high doses of TNFa induced significant loss of functional integrity and that infliximab seemed to have a protective effect on sperm, counteracting the damage induced by TNF-a. 38, 39 A systematic review by Puchner et al 40 of expectant fathers who used TNF-blocking agents before conception did not find any documentation of miscarriages or physical abnormalities associated with anti-TNF-a therapy; instead, the authors found evidence that sperm motility and vitality might even improve under therapy.
In this study, patients with CD on anti-TNF therapy achieved better progressive motility and sperm morphology, with a trend toward better sperm vitality, compared with patients with CD who were not on anti-TNF therapy. These results seem to confirm those observed in rheumatologic diseases 41, 42 and, consequently, support the view that patients treated with anti-TNF drugs do not experience fertility problems as a result of such therapy. 43 Conversely, anti-TNF drugs seem to have a protective effect on sperm count and motility, which may be explained by a compensatory effect against the damage induced by TNF-a on sperm. Further assessment in a larger sample is important, given the increased use of anti-TNF drugs in patients with IBD in their peak reproductive years.
Finally, there are conflicting data on the impact of IBD on sexuality, especially in men. [44] [45] [46] [47] Bel et al 48 performed a study to evaluate sexual function and its association with depression among patients with IBD compared with controls. The authors found that men and women with active IBD experience impaired sexual function in relation to patients in remission and controls and that depression is the most important factor contributing to impaired sexual function in patients with IBD.
Another prospective study 49 assessing sexual function in patients with IBD showed a trend toward poorer sexual function in patients with an active disease compared with those with an inactive disease, and a high prevalence of depression (61.7%) and atigue (45%) among patients with IBD.
In this study, sexual function (as determined by the IIEF-15 questionnaire) was not affected by IBD or anti-TNF therapy in men with remitted IBD and these patients did not show a higher prevalence of sexual dysfunction as compared with control subjects.
This study has several limitations. Because no information was obtained about the characteristics of the patients or controls not willing to participate, it is not possible to establish whether specific groups were under-represented or whether individuals with sexual problems declined to participate.
This study evaluated IBD activity with clinical scores alone. Perhaps evaluation through endoscopy or imaging would find differences in activity between patients with CD with and without anti-TNF therapy, which could explain the differences in seminal parameters. In addition, the study evaluated plasma TNFa levels rather than seminal levels, which have a demonstrably deleterious effect on sperm quality.
Another limitation of this study is its cross-sectional design, which could not provide information regarding influence on fertility and future paternity in these patients. It cannot be established whether these results could affect future fertility in patients with CD.
Due also to the transversal design of the study, the number of children each subject has fathered is not included in the analysis. In fact, many of these patients were young people who had not thought about fathering children at the time of their enrolment in the study. A follow-up in the long term will provide more information but that exceeds the aims of this study.
In conclusion, our findings show that men with CD tend to have poorer semen quality than those with UC. This impairment is characterized by lower sperm count, reduced progressive motility, and lower seminal zinc levels. These alterations do not seem to be related to IBD activity, anti-sperm antibodies, zinc deficiency, or plasma levels of TNF-a.
Treatment with thiopurines and anti-TNF drugs is not associated in this study with poor sperm quality in patients with CD. In fact, patients on anti-TNF therapy exhibit better progressive motility in semen analysis than patients not receiving such treatment. Although our study shows that best semen quality was found in patients taking anti-TNF drugs, these results should be carefully considered due to the small size of the sample included in this analysis.
At least in patients with remitted disease, sexual function was not affected by IBD.
